Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 71 results for parkinson

  1. How frequently the remote monitoring devices were modelled as being used substantially affected the cost-effectiveness estimates in the EAG's model (see section 3.9 ). There are many ways the devices could be used in the NHS (see section 3.3 ) and no data was available to compare different approaches. So, it is currently not possible to highlight particular approaches that are likely to be more clinically and cost effective. Centres using the devices should therefore collect data on how often they are used and under what circumstances. For example, regularly in advance of scheduled review appointments, to indicate when such appointments are needed, or targeted to people having issues with symptoms. This will help assess the clinical and cost effectiveness of the different uses of the devices in NHS practice.

    details Comes from guidance Devices for remote monitoring of Parkinson's disease Number DG51 Date issued January 2023

    Research recommendation
    Published
    7 March 2023

  2. Management strategies to reduce the risk of symptomatic urinary tract infections:- In people with neurogenic lower urinary tract dysfunction, which management strategies (including the use of prophylactic antibiotics and various invasive and non-invasive techniques to aid bladder drainage) reduce the risk of symptomatic urinary tract infections?

    the population with neurological diseases such as multiple sclerosis, Parkinson's disease and dementia, the rise in temperature with...

    Research recommendation
    Published
    9 June 2015

  3. Older people with social care needs and multiple long-term conditions (NG22)

    This guideline covers planning and delivering social care and support for older people who have multiple long-term conditions. It promotes an integrated and person-centred approach to delivering effective health and social care services.

    NICE guideline
    Published
    4 November 2015
    View recommendations

    Sections for NG22

  4. ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB61)

    NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation

    Medtech innovation briefing
    Published
    23 March 2016

  5. Schizophrenia: lurasidone (ESNM48)

    Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

    Evidence summary
    Published
    23 September 2014

  6. Managing medicines for adults receiving social care in the community (NG67)

    This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.

    NICE guideline
    Published
    30 March 2017
    View recommendations

    Sections for NG67

  7. U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)

    NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .

    Medtech innovation briefing
    Published
    9 February 2017

  8. Cerebral palsy in adults (NG119)

    This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.

    NICE guideline
    Published
    15 January 2019
    View recommendations

    Sections for NG119

  9. Dementia. Patient decision aid on antipsychotic medicines for treating agitation, aggression and distress in people living with dementia

    headache  changes in appetite, and weight gain  symptoms like those of Parkinson's disease. These may include slowness or difficulty...

  10. Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)

    Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.

    Technology appraisal guidance
    Published
    25 March 2015
    View recommendations

    Sections for TA337

  11. Parkinson's disease with motor fluctuations: safinamide (ES6)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Evidence summary
    Published
    21 February 2017

  12. Devices for remote monitoring of Parkinson's disease (DG51)

    We have moved Diagnostics guidance 51 to become HealthTech guidance 657. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Diagnostics guidance
    Last updated
    25 January 2024

  13. Parkinson's disease in over 20s: diagnosis and management (CG35)

    This guidance has been updated and replaced by NICE guideline NG71.

    Clinical guideline
    Published
    28 June 2006

  14. Excessive daytime sleepiness in Parkinson's disease: modafinil (ESUOM48)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Evidence summary
    Published
    29 September 2015

  15. Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Evidence summary
    Published
    21 March 2017